within Pharmacolibrary.Drugs.ATC.A;

model A02BC01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.008333333333333333,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 840,            
    Vdp             = 0.00022,
    k12             = 17,
    k21             = 17
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the parietal cells of the stomach. It is widely used for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. It is approved and commonly prescribed globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after a single oral dose of 20 mg omeprazole.</p><h4>References</h4><ol><li><p>Oosterhuis, B, &amp; Jonkman, JH (1989). Omeprazole: pharmacology, pharmacokinetics and interactions. <i>Digestion</i> 44 Suppl 1 9–17. DOI:<a href=\"https://doi.org/10.1159/000200098\">10.1159/000200098</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2691315/\">https://pubmed.ncbi.nlm.nih.gov/2691315</a></p></li><li><p>Cederberg, C, et al., &amp; Skånberg, I (1989). Omeprazole: pharmacokinetics and metabolism in man. <i>Scandinavian journal of gastroenterology. Supplement</i> 166 33–42. DOI:<a href=\"https://doi.org/10.3109/00365528909091241\">10.3109/00365528909091241</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2690330/\">https://pubmed.ncbi.nlm.nih.gov/2690330</a></p></li><li><p>Zhao, L, et al., &amp; Lionberger, R (2023). Effect of Omeprazole Administration on the Pharmacokinetics of Oral Extended-Release Nifedipine in Healthy Subjects. <i>Clinical pharmacology and therapeutics</i> 114(5) 1134–1141. DOI:<a href=\"https://doi.org/10.1002/cpt.3043\">10.1002/cpt.3043</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37669218/\">https://pubmed.ncbi.nlm.nih.gov/37669218</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BC01;
